Bayer refused compensation of 400 million rubles from Nativa

​​German pharmaceutical manufacturer Bayer refused to receive compensation from the Spectr company, which until June 2022 was called Nativa, in the amount of over 400 million rubles. for the use of a patent for the oncological drug sorafenib, should from the file of arbitration cases.

According to the settlement agreement between the parties, which was concluded on October 25, Nativa promised not to introduce its generic version of the drug into circulation and not to register its new analogues until 2026, when Bayer’s second patent for sorafenib expires.

A similar agreement was signed following a six-year trial that began in 2018 after Nativa launched its generic sorafenib-native on the market. According to Headway Company, last year the share of purchases of the generic Nativa was 30%, while for the original drug Nexavar it did not exceed 13%.

How writes Kommersant, a generic version of Nativa, was one of the leaders at state auctions. According to Headway Company, last year the share of purchases of the generic Nativa was 30%, while for the original drug Nexavar it did not exceed 13%.

Previously, a company called Nativa was involved in registering drugs under patent protection, for example, the antitumor drug nilotinib (produced by the international Novartis AG, headquartered in Switzerland) and the antitumor sorafenib (German Bayer). As a result, as follows from the database of arbitration courts, a total of 15 claims related to the protection of intellectual property were filed against her. Among them was a claim filed in June 2022 in the amount of 400.4 million rubles. from Bayer. Now Nativa is at the stage of bankruptcy.